# Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease

> **NCT02148185** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 1 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** MT-1303

## Key facts

- **NCT ID:** NCT02148185
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2014-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02148185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02148185, "Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02148185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*